Harvard Medical School professor Joel F. Habener won the 2024 Lasker-DeBakey Clinical Medical Research Award for his work on ...

The CEO of Novo Nordisk took questions for more than two hours during a Senate Health Committee hearing focused on addressing ...

Novo Nordisk and Eli Lilly are expected to rule the obesity market for a few more years without much challenge. To ensure they stay there as competition enters, the companies are spending billions in ...

Large employers could spend as much as an additional 7.8% in health costs next year, according to a Business Group on Health survey.

The CEO of Novo Nordisk wouldn’t commit to lowering the prices of Ozempic and Wegovy during a Senate hearing Tuesday, despite ...

What I am asking you is, if you don’t act, 40,000 people a year could die? Is this acceptable to you?” the senator asked.

The boss of the Danish pharmaceutical giant behind the blockbuster diabetes and weight-loss drugs Ozempic and Wegovy promised ...

Sen. Bernie Sanders mentioned that North Carolina ended coverage of Wegovy for state employees due to the cost.

The maker of diabetes and weight-loss drugs Ozempic and Wegovy was in the hot seat Tuesday as Vermont Sen. Bernie Sanders ...

U.S. senators questioned Novo Nordisk CEO Lars Fruergaard Jørgensen about the high costs of the company's GLP-1 drugs, which include popular weight-loss drugs Wegovy and Ozempic. It comes after North ...

The CEO of Novo Nordisk was questioned about the high cost in the U.S. of Wegovy and Ozempic, the wildly popular diabetes and ...